(), |
|
* 2017 .
.
(). . , , . , , . , . , . . , , , , . . .
: , , , , , , , .
: .., .. () // . 2016. 20. . 1327-1333
Infections in diabetics (lecture)
Kukushkin G.V. 1 , Starostina E.G. 2
1 N.I. Pirogov Russian National Research Medical University, Moscow
2 M.F. Vladimirskiy Moscow Regional Research and Clinical Institute, Moscow
This lecture for endocrinologists and general practitioners discusses infectious diseases in diabetics. Results from large clinical trials which demonstrate higher incidence of various infections and carriage in diabetics are addressed. Clinical value and infection course in diabetes resulting in higher mortality, greater risks, and chronicity are uncovered. The paper analyzes the mechanisms of anti-infection protection in diabetics which breaks under hyperglycemia as well as pathogen spectrum. Key diagnostic aspects and treatment approaches to the most common infections in diabetics are reviewed. Bacterial and fungal urinary infections (including those in pregnant women), mucormycosis, soft tissue and wound infections, pneumonia, and tuberculosis are of special importance. Basic antimicrobial regimens for infections of various localization and severity are described in detail. Specific early vaccination provided by endocrinologist is required in diabetics.
Key words: diabetes, infections, hyperglycemia, urinary tract infections, pyelonephritis, tuberculosis, antibacterial therapy, vaccination.
For citation: Kukushkin G.V., Starostina E.G. Infections in diabetics (lecture) // RMJ. 2016. 20. P. 13271333.
() . - . , - . , , . , : 1) , , , -; 2) ; 3) ( ). , . , , , , . , .
, , , , . , Escherichia coli Klebsiella pneumoniae, . .
, 550 (DCCT 1 ), , 15 3% . , , HbA1c, -, - , . ( ), , . NHANES III .
, () () (), . . .
, , . . . 4872 .
4 , . , ( 6080% ) . , : (Klebsiella pneumoniae, Proteus spp., Enterobacter spp.), (Enterococcus spp., Staphylococcus spp.), Candida, - , , . , Enterococcus spp., Proteus spp. Enterobacter spp. 20%. - ( E. coli 26,8%), . , -, . . , , (, ) -, . ( ), . . .
, , , ( , ), .
(), ( ). , .
(, , ), , , , ( 2- , ) , .
- :
1. .
2. .
3. . ( , ). .
4. .
5. (, , ) .
(. 1).
, II III , ( 38 . - ). , - (I III ) .
(3 ), (100 2 ./ 7 ), / (500/125 3 ./ 37 ), (400 1 ./ 37 ) (400 1 ./ 57 ). .
. , Candida ( Candida albicans). , . . , , , .
, . 70% , . , , , , . Candida spp. . .
( ). ( , , , ), ; . , .
, , . Candida albicans, 2- Candida glabrata, .
, . . . (1 ), , . . , .
, ( C. albicans), . , , , , . 200 , 100 / 4- . , 200 / 714 . 150 3- ; . ( albicans), . .
, , , , . . .
, , , . 34 , , , , , . .
, .
. : . / (0,625 3 ./), (1 4 ./), (0,5 2 ./). - (0,3 34 ./) : (0,5 1 ./), (0,4 1 ./). MRSA (0,3 34 ./), (0,3 3 ./) (0,6 2 ./). (, / ) () (0,5 3 ./) , .
, , MRSA, . (15 / 2 ./, / 1 ), (0,6 2 ./ / ), (4 /, / 30 ) MRSA. / (1,53 34 ./ /), / (4,5 34 ./ /), (0,5 3 ./ /) (1 1 ./ /). , , , .
. , , 714 , 24 . . .
, , . (), . . : , , . , . .
(. 2). , (, ) . (, ) (, ).
. .
, , /, /, , , / + / , / + , /.
(, , 7 , ) / /, , , / + , , /, , , / + II-III (, , ) + , /, , , / + II-III + .
- . Pseudomonas aeruginosa, . : , , . . / 0,5/0,5 / 4 ./, 1 / 3 ./, 400 / 2 ./, 2 / 3 ./, 2 / 3 ./, / 4,5 4 ./. , , -, - - . , 30% P. aeruginosa, , , 750 12 . 46 .
, . (ADA) , 6- . . 79% , . , 1959 60 . 2 , .
.
1 Diabetes Control and Complications Trial ( )
|
2 |
|
: " 2 " . , , . - .
✓
(NATION) 50% 2 . , 8-9 . ( 6% ), , , , , . , . , , . .
( ). |
( ). |
2 :
:
2
, , :
! , . .
, . 250-500 .
,
. 500 , .
. . , , .
! 65 , . .
, , . 500 850 , . .
, , . , . .
, .
! , . .
-1. , . , , , . , . . 4800 6000 .
, . . 9500 . . , .
. 1700 . , . 100 . , .
-4. , . . 5 .
-4. . 50 . , . 900 . , .
! . .
15 40 . . 15 , . . 3000 .
, 100-300 . . 0,5 . 0,87 , . , 2-3 . .
700 . . . . 50 100 . . .
. 15 . 45 . . 700 .
, . . 15 30 . 45 . .
! , , .
. , 2 .
, , . , , .
. 2 .
, 2 , .
2 , , . , 2 .
2 , .
:
2 . , , .
, . :
. , , , , .
, , 2 , , .
.
, . .
, , 1 , , , .
, , , . , , .
, .
. .
2 , .
.
.
, 2 . , , , .
. . .
, , .
2 , .
, .
:
, :
50-100%
. .
, , , , .
.
, .
, , :
, :
- . -, . , . .
, .
50 . -. . , . , , .
, - . . .
. , .
.
, , , , , .
, , . . , , .
. , . , . .
, , , . 2 .
, , , .
-, . . 2 .
2 . , , . . .
? . 2 , , .
. , 2 . , .
, . , . , .
, , 8 :
- .
- .
- .
- .
- IV.
- .
- .
- α-.
.
, 2 , 50- . .
:
.
, .
, 2 , .
. .
:
:
.
, . . , , , , .
2 , :
, .
, . . .
2 .
, . . , .
40%! 2 , , .
, . . , .
, - .
2 . , , . , .
, , , , . , .
, . , , , .
, , , . - , , .
, . , , . .
. . 10 -. , . . .
|
2 ? |
|
. . , , , . , , . , , , .
. , . . , . : 100 85 . 2 1- , . , , . .
, , 4 100 . , , .. . - , , .
. , , . .
2 1- . , , , .
:
. , .
. , , .
2 , 1- , . , . . . .
, , . . , .
2 1- . . , .
, , . .
. . , . . , . . .
. . . , . .
, , . , . 50 , , . . .
, . , . . , .
|
2- , |
|
2- , . 2- , () , . () 2- :
2- :
:
2- :
, . . :
|
D: , () |
|
, D 2- .
(Centers for Disease Control and Prevention CDC), 2- 100 . , , .
, D 2- . , 2010 . , D .
?
, D . , D. .
, D , . 6 .
, , . , - .
- 96 . , , D. European Journal of Endocrinology.
2 . 5000 D3 6 , 510 . .
, D 6 . -.
, D.
: .ua - - , , ,
|
, - |
|
2 90% 1. 2 , . . , . 2 . 2 .
1 , , . 3% , . 2 1. 1 , , . : . O .
. . : . , . , , . .
246 , 2025 , 380 1. , 4% 2, - . : 1 , - , . , .
, , , . , , . , : , .
, , HbA1C , . , HbA1C? : A1c A1C Hb1 ( ) , 1.
, () . . , (). . .
, - . , . .
, , , . , , .
, , , , -, , : - www.te-ex.ru.
2019 . . : 26.07.2019
. .
|
: | [1] |